Tidal Investments LLC Sells 12,000 Shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX)

Tidal Investments LLC trimmed its stake in shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX) by 4.7% in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 246,001 shares of the biotechnology company’s stock after selling 12,000 shares during the period. Tidal Investments LLC owned 0.31% of CytomX Therapeutics worth $290,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Acadian Asset Management LLC lifted its position in shares of CytomX Therapeutics by 1.4% during the second quarter. Acadian Asset Management LLC now owns 2,728,569 shares of the biotechnology company’s stock worth $3,324,000 after purchasing an additional 37,739 shares during the last quarter. Assenagon Asset Management S.A. increased its stake in CytomX Therapeutics by 32.8% in the 3rd quarter. Assenagon Asset Management S.A. now owns 1,644,168 shares of the biotechnology company’s stock worth $1,940,000 after buying an additional 405,669 shares during the period. Jacobs Levy Equity Management Inc. lifted its holdings in CytomX Therapeutics by 1.1% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 1,524,076 shares of the biotechnology company’s stock valued at $1,798,000 after buying an additional 16,359 shares in the last quarter. Congress Park Capital LLC boosted its position in CytomX Therapeutics by 5.4% in the 3rd quarter. Congress Park Capital LLC now owns 1,216,008 shares of the biotechnology company’s stock valued at $1,435,000 after buying an additional 62,788 shares during the period. Finally, Geode Capital Management LLC grew its stake in CytomX Therapeutics by 4.4% in the 3rd quarter. Geode Capital Management LLC now owns 803,531 shares of the biotechnology company’s stock worth $948,000 after acquiring an additional 34,032 shares in the last quarter. 67.77% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reiterated a “neutral” rating on shares of CytomX Therapeutics in a report on Monday, November 11th. Four analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $5.77.

CytomX Therapeutics Stock Performance

Shares of CTMX opened at $1.07 on Wednesday. The stock has a market capitalization of $83.74 million, a PE ratio of 6.29 and a beta of 1.07. The company has a 50 day moving average price of $1.06 and a 200-day moving average price of $1.20. CytomX Therapeutics, Inc. has a fifty-two week low of $0.83 and a fifty-two week high of $5.85.

CytomX Therapeutics (NASDAQ:CTMX) last announced its earnings results on Thursday, November 7th. The biotechnology company reported $0.07 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.16) by $0.23. The business had revenue of $33.43 million for the quarter, compared to analysts’ expectations of $18.92 million. CytomX Therapeutics had a negative return on equity of 41.47% and a net margin of 10.96%. During the same quarter last year, the firm earned $0.04 EPS. Equities research analysts forecast that CytomX Therapeutics, Inc. will post -0.05 EPS for the current year.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.